SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : A Good Cancer research Bio company?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: B. Ino who wrote ()11/4/1996 8:51:00 AM
From: Henry Niman   of 76
 
Although LGND has cancer as its niche market, there are many more
applcations for its products:
I heard a couple of interesting reports last week. The first was on the
radio and it described a research observation that indicated
anti-estrogens could stimulate hair growth on the backs of shaved mice.
The second report was televised (MSNBC or TLC) and it was somewhat more
detailed. A graduate student or technician had noticed that application
of estrogens to the backs of shaved mice prevented hair re-growth.
Application of an anti-estrogen (they showed a label from ZEN so I assumed
it was Tamoxifin) resulted in stimulation of hair growth. They also noted
that Rogaine worked by stimulation of blood flow to hair follicals and the
mechanism of the anti-estrogen would be different (by acting through the
estrogen receptors). They also noted that Rogain only works in about 30%
of patients. Others are exploring treatment of male and female pattern
baldness by treating with anti-androgens. The above should be good news
for LGND. They have very extensive sex steroids programs. Droloxifene is
an analog of Tamoxifin and it is in advanced clinical trials (Phase II for
osteoporosis and Phase III for breast cancer). LGND will receive milestone
and royalty payments from PFE for ANY approved application. The alliance
with PFE has also identified a second estrogen analog which is slated to
begin clinical trials in Europe this year and in the U.S. next year. LGND
has an even bigger program with AHP. That program targets estrogen
analogs identified by LGND as well as AHP. AHP sells Premarin (for
hormone replacement therapy and osteoporosis) through its Wyeth-Ayerst
subsidiary (over $1 Billion in annual sales). The cosmeceutical
applications (estrogens to the face to eliminate shaving or anti-estrigens
to balding baby boomers to stimulate hair growth) of the above should
intrigue investors (LGND also has a large in-house anti-androgen program).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News